Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aerie Pharmaceuticals (AERI)
NASDAQ:AERI
Aerie Pharma (AERI) Stock Price & Analysis
0 Followers
AERI Stock Chart & Stats
Day’s Range$15.24 - $15.25
52-Week Range― - ―
Previous Close$15.24
Volume1.22M
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding49,417,407
10 Day Avg. Volume121,518
30 Day Avg. Volume362,501
Standard Deviation0.22
R-Squared0.00025
Alpha-0.00499
Financial Highlights & Ratios
Price to Book (P/B)-4.60
Price to Sales (P/S)3.52
Price to Cash Flow (P/CF)100.90
P/FCF Ratio285.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Aerie Pharma News
Stock Analysis & IdeasUBX vs. AERI: Which Eyecare Stock Has the Most Upside Potential?
Stock Analysis & Ideas3 “Strong Buy” Stocks Poised for a Year-End Rally
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AERI FAQ
What was Aerie Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Aerie Pharmaceuticals’s market cap?
Currently, no data Available
When is Aerie Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aerie Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Aerie Pharmaceuticals overvalued?
According to Wall Street analysts Aerie Pharmaceuticals’s price is currently Overvalued.
Does Aerie Pharmaceuticals pay dividends?
Aerie Pharmaceuticals does not currently pay dividends.
What is Aerie Pharmaceuticals’s EPS estimate?
Aerie Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aerie Pharmaceuticals have?
Currently, no data Available
What happened to Aerie Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aerie Pharmaceuticals?
Among the largest hedge funds holding Aerie Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Aerie Pharmaceuticals’s shares valued at 73M.
---
Aerie Pharma Stock Smart Score
Company Description
Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
---